

Elena Bartoloni

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9467949/elena-bartoloni-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

160
papers

3,223
citations

34
h-index

53
g-index

175
ext. papers

4,002
ext. citations

4.7
avg, IF

5.07
L-index

#	Paper	IF	Citations
160	An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations.. <i>Clinical Reviews in Allergy and Immunology</i> , 2022 , 1	12.3	0
159	Addressing the clinical unmet needs in primary Sjögren's Syndrome through the sharing, harmonization and Federated analysis of 21 European cohorts.. <i>Computational and Structural Biotechnology Journal</i> , 2022 , 20, 471-484	6.8	0
158	Development and Implementation of the AIDA International Registry for Patients With Still's Disease.. <i>Frontiers in Medicine</i> , 2022 , 9, 878797	4.9	0
157	Unattended compared to traditional blood pressure measurement in patients with rheumatoid arthritis: a randomised cross-over study. <i>Annals of Medicine</i> , 2021 , 53, 2050-2059	1.5	1
156	Identification of a Novel Serological Marker in Seronegative Rheumatoid Arthritis Using the Peptide Library Approach. <i>Frontiers in Immunology</i> , 2021 , 12, 753400	8.4	1
155	Long-term Outcome of Children Born to Women with Autoimmune Rheumatic Diseases: A Multicentre, Nationwide Study on 299 Randomly Selected Individuals. <i>Clinical Reviews in Allergy and Immunology</i> , 2021 , 1	12.3	0
154	Peripheral Nervous System Involvement in Sjögren's Syndrome: Analysis of a Cohort From the Italian Research Group on Sjögren's Syndrome. <i>Frontiers in Immunology</i> , 2021 , 12, 615656	8.4	1
153	Contribution of Janus-Kinase/Signal Transduction Activator of Transcription Pathway in the Pathogenesis of Vasculitis: A Possible Treatment Target in the Upcoming Future. <i>Frontiers in Pharmacology</i> , 2021 , 12, 635663	5.6	4
152	Baseline characteristics of systemic lupus erythematosus patients included in the Lupus Italian Registry of the Italian Society for Rheumatology. <i>Lupus</i> , 2021 , 30, 1233-1243	2.6	0
151	Comment on: Equal rights in autoimmunity: is Sjögren's syndrome ever 'secondary'?. <i>Rheumatology</i> , 2021 , 60, e32-e33	3.9	
150	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus. <i>Autoimmunity Reviews</i> , 2021 , 20, 102738	13.6	14
149	Intravenous Immunoglobulins at the Crossroad of Autoimmunity and Viral Infections. <i>Microorganisms</i> , 2021 , 9,	4.9	8
148	Different clinical presentations of primary Sjögren's syndrome: Not only a matter of age. Comment on: "Elderly-onset primary Sjögren's syndrome focused on clinical and salivary gland ultrasonographic features by Lee et al. <i>Joint Bone Spine</i> . 2021;88:105132". <i>Joint Bone Spine</i> , 2021 , 88, 105132	2.9	
147	Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLISS-LN). Results from a large, nationwide, multicentric cohort. <i>Journal of Autoimmunity</i> , 2021 , 124, 102729	15.5	3
146	Correspondence on 'Anti-inflammatory therapy for COVID-19 infection: the case for colchicine'. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	
145	Retinal detachment as the first manifestation of systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 924	2.2	
144	COVID-19: the new challenge for rheumatologists. One year later. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 203-213	2.2	1

143	One year in review 2021: Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021 ,	2.2	3
142	Traditional and disease-related non-computed variables affect algorithms for cardiovascular risk estimation in Sjögren's syndrome and rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 107-113	2.2	0
141	Adherence to the Mediterranean diet and the impact on clinical features in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 190-196	2.2	1
140	One year in review 2021: Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 3-13	2.2	2
139	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 166-174	2.2	0
138	COVID-19: the new challenge for rheumatologists. One year later. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 203-213	2.2	2
137	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium.. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39 Suppl 133, 166-174	2.2	
136	The Impact of SARS-CoV-2 Outbreak on Primary Sjögren's Syndrome: An Italian Experience. <i>Frontiers in Medicine</i> , 2020 , 7, 608728	4.9	4
135	Prevention and treatment of autoimmune diseases with plant virus nanoparticles. <i>Science Advances</i> , 2020 , 6, eaaz0295	14.3	10
134	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. <i>Frontiers in Medicine</i> , 2020 , 7, 42	4.9	6
133	Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1314-1324	9.5	24
132	Novel insights on lymphoma and lymphomagenesis in primary Sjögren's Syndrome. <i>Panminerva Medica</i> , 2020 ,	2	2
131	Interplay of anti-SSA/SSB status and hypertension in determining cardiovascular risk in primary Sjögren's syndrome. <i>Journal of Internal Medicine</i> , 2020 , 287, 214-215	10.8	1
130	COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy. <i>Immunologic Research</i> , 2020 , 68, 213-224	4.3	90
129	Hypertension and SARS-CoV-2 infection: is inflammation the missing link?. <i>Cardiovascular Research</i> , 2020 , 116, e193-e194	9.9	3
128	Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M. The impact of cardiovascular comorbidity on COVID-19 infection in a large cohort of rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	1
127	Association Between Glandular Infiltrate and Leukopenia in Sjögren Syndrome (SS): Data From the Italian Research Group on SS (GRISS). <i>Journal of Rheumatology</i> , 2020 , 47, 1840-1841	4.1	4
126	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. <i>Journal of Autoimmunity</i> , 2020 , 111, 102468	15.5	76

125	The differential response to anti IL-6 treatment in COVID-19: the genetic counterpart. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38, 580	2.2	6
124	Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38, 754-759	2.2	26
123	One year in review 2020: comorbidities, diagnosis and treatment of primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 126, 10-22	2.2	10
122	The use of digital image analysis in the histological assessment of Sjögren's syndrome salivary glands improves inter-rater agreement and facilitates multicentre data harmonisation. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 126, 180-188	2.2	4
121	Characterisation of articular manifestations in primary Sjögren's syndrome: clinical and imaging features. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 126, 166-173	2.2	
120	Significance of anti-La/SSB antibodies in primary Sjögren's syndrome patients with combined positivity for anti-Ro/SSA and salivary gland biopsy. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 126, 53-56	2.2	
119	A Training Tool to support the management and diagnosis of Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 126, 174-179	2.2	
118	Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 126, 85-94	2.2	1
117	Validation of thymic stromal lymphopoietin as a biomarker of primary Sjögren's syndrome and related lymphoproliferation: results in independent cohorts. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 126, 189-194	2.2	
116	Different operators and histologic techniques in the assessment of germinal center-like structures in primary Sjögren's syndrome minor salivary glands. <i>PLoS ONE</i> , 2019 , 14, e0211142	3.7	8
115	Subclinical Atherosclerosis in Primary Sjögren's Syndrome: Does Inflammation Matter?. <i>Frontiers in Immunology</i> , 2019 , 10, 817	8.4	6
114	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. <i>Frontiers in Pharmacology</i> , 2019 , 10, 296	5.6	17
113	Celiac Disease Prevalence is Increased in Primary Sjögren's Syndrome and Diffuse Systemic Sclerosis: Lessons from a Large Multi-Center Study. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	9
112	Th17 Cells 2019 , 37-44		
111	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	48
110	The dark side of Sjögren's syndrome: the possible pathogenic role of infections. <i>Current Opinion in Rheumatology</i> , 2019 , 31, 505-511	5.3	8
109	Effect of Sinovial High-Low□ injections in trapeziometacarpal osteoarthritis. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37, 166	2.2	4
108	Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 118, 97-106	2.2	4

107	One year in review 2019: Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 118, 3-15	2.2	13
106	The kaleidoscope of neurological manifestations in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 118, 192-198	2.2	7
105	Application of artificial neural network analysis in the evaluation of cardiovascular risk in primary Sjögren's syndrome: a novel pathogenetic scenario?. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 118, 133-139	2.2	1
104	A Platelet's Guide to Synovitis. <i>Israel Medical Association Journal</i> , 2019 , 21, 454-459	0.9	0
103	Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases. <i>Nature Reviews Cardiology</i> , 2018 , 15, 33-44	14.8	33
102	Targeting Inflammation to Prevent Cardiovascular Disease in Chronic Rheumatic Diseases: Myth or Reality?. <i>Frontiers in Cardiovascular Medicine</i> , 2018 , 5, 177	5.4	9
101	Extra-articular rheumatoid arthritis. <i>Reumatismo</i> , 2018 , 70, 212-224	1.1	25
100	Prevalence and significance of anti-saccharomyces cerevisiae antibodies in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 112, 73-79	2.2	2
99	The prevalence and relevance of traditional cardiovascular risk factors in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 112, 113-120	2.2	6
98	One year in review 2018: Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 112, 14-26	2.2	10
97	How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 112, 102-112	2.2	34
96	Discrepancy between subjective symptoms, objective measures and disease activity indexes: the lesson of primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 112, 210-214	2.2	2
95	Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group. <i>Clinical Reviews in Allergy and Immunology</i> , 2017 , 52, 71-80	12.3	48
94	Relevance of Interferon-Inducible Protein-16 Rather than Anti-Interferon-Inducible Protein-16 Autoantibodies as a Clinical and Pathogenic Biomarker in Primary Sjögren's Syndrome: Comment on the Article by Baer et al. <i>Arthritis Care and Research</i> , 2017 , 69, 453-454	4.7	
93	Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study. <i>Autoimmunity Reviews</i> , 2017 , 16, 253-257	13.6	37
92	Cryoglobulinemia in Sjögren Syndrome: A Disease Subset that Links Higher Systemic Disease Activity, Autoimmunity, and Local B Cell Proliferation in Mucosa-associated Lymphoid Tissue. <i>Journal of Rheumatology</i> , 2017 , 44, 1179-1183	4.1	24
91	Role of Inflammatory Diseases in Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017 , 24, 353-361	2.9	7
90	Platelets Contribute to the Accumulation of Matrix Metalloproteinase Type 2 in Synovial Fluid in Osteoarthritis. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 2116-2124	7	14

89	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , 2017 , 8, 369	5.6	68
88	The clinical spectrum of primary Sjögren's syndrome: beyond exocrine glands. <i>Reumatismo</i> , 2017 , 69, 93-100	1.1	6
87	Insulin-Like Growth Factor Binding Protein 6 in Rheumatoid Arthritis: A Possible Novel Chemotactic Factor?. <i>Frontiers in Immunology</i> , 2017 , 8, 554	8.4	14
86	Correlation between ESSDAI and ClinESSDAI in a real-life cohort of patients with Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 546-547	2.2	3
85	Novel Therapeutic Strategies in Primary Sjögren's Syndrome. <i>Israel Medical Association Journal</i> , 2017 , 19, 576-580	0.9	2
84	THU0341 Correlation between Essdai and Clinessdai in A Real-Life Cohort of Sjögren's Syndrome Patients. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 310.2-310	2.4	0
83	Central Hemodynamics and Arterial Stiffness in Systemic Sclerosis. <i>Hypertension</i> , 2016 , 68, 1504-1511	8.5	12
82	Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 382-9	2.4	144
81	SAT0290 A Higher Disease Activity in Anti-Ssa/ssb Positive Sjögren's Syndrome Is Explained by A Higher Clinical and Biological B-Cell Activation. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 773.2-773	2.4	
80	Clinical Features 2016 , 11-33		2
79	The onset site of rheumatoid arthritis: the joints or the lung?. <i>Reumatismo</i> , 2016 , 68, 167-175	1.1	4
78	T Cells in the Pathogenesis of Sjögren's Syndrome 2016 , 205-215		
77	Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study. <i>Clinical and Experimental Immunology</i> , 2016 , 184, 284-92	6.2	28
76	The Need to Target Mucosa-Associated Lymphoid Tissue for Preventing Lymphoma in Rheumatoid Factor-Positive Patients With Sjögren's Syndrome: Comment on the Article by Nocturne et al. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1318-9	9.5	3
75	Circulating Interferon-Inducible Protein IFI16 Correlates With Clinical and Serological Features in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016 , 68, 440-5	4.7	14
74	AB0592 Evaluation of Arterial Stiffness in A Cohort of Systemic Sclerosis Patients: A Case-Control Study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1107.1-1107	2.4	
73	One year in review 2016: Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 161-71	2.2	20
72	A8.6 A novel therapeutic approach in systemic rheumatic autoimmune disorders: encapsulated human umbilical cord wharton jelly-derived mesenchymal stem cells. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, A83.2-A83	2.4	

71	Anti-SSA/SSB-negative Sjögren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. <i>Autoimmunity Reviews</i> , 2015 , 14, 1019-22	13.6	56
70	Altered immunoregulation in rheumatoid arthritis: the role of regulatory T cells and proinflammatory Th17 cells and therapeutic implications. <i>Mediators of Inflammation</i> , 2015 , 2015, 751793	4.3	178
69	Anticyclic Citrullinated Peptide Antibodies in Patients with Rheumatic Diseases other than Rheumatoid Arthritis: Clinical or Pathogenic Significance?. <i>Journal of Rheumatology</i> , 2015 , 42, 1063-4	4.1	1
68	A retrospective, multicenter study evaluating the prognostic value of minor salivary gland histology in a large cohort of patients with primary Sjögren's syndrome. <i>Lupus</i> , 2015 , 24, 315-20	2.6	55
67	Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 859-66	2.4	138
66	Characterization of circulating endothelial microparticles and endothelial progenitor cells in primary Sjögren's syndrome: new markers of chronic endothelial damage?. <i>Rheumatology</i> , 2015 , 54, 536-44	2.9	29
65	Clinical and biological differences between cryoglobulinaemic and hypergammaglobulinaemic purpura in primary Sjögren's syndrome: results of a large multicentre study. <i>Scandinavian Journal of Rheumatology</i> , 2015 , 44, 36-41	1.9	38
64	In vitro immunomodulatory effects of microencapsulated umbilical cord Wharton jelly-derived mesenchymal stem cells in primary Sjögren's syndrome. <i>Rheumatology</i> , 2015 , 54, 163-8	3.9	37
63	FRI0180 Correlation Between Clinimetric Approach and German US7 Score in Rheumatoid Arthritis Patients Treated with Tocilizumab: A Pilot Study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 489.1-489	2.4	
62	Interferon gamma-inducible protein 16 in primary Sjögren's syndrome: a novel player in disease pathogenesis?. <i>Arthritis Research and Therapy</i> , 2015 , 17, 208	5.7	20
61	FRI0024 Interferon Gamma-Inducible Protein 16 (IFI16) in Rheumatoid Arthritis: A Novel Biomarker for Pulmonary Involvement?. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 427.1-427	2.4	0
60	THU0393 IL-17 Producing Pathogenic T Lymphocytes Co-Express CD20 and are Depleted by Rituximab in Primary sjögren's Syndrome: A Novel Target for an Old Weapon. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 339.1-339	2.4	
59	Cardiovascular disease risk burden in primary Sjögren's syndrome: results of a population-based multicentre cohort study. <i>Journal of Internal Medicine</i> , 2015 , 278, 185-92	10.8	71
58	Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome: Results From an International Retrospective Multicenter Study. <i>Medicine (United States)</i> , 2015 , 94, e1144	1.8	91
57	AB0564 Disease Damage is Associated with Increased Aortic Stiffness in Systemic Lupus Erythematosus: A Cross-Sectional Study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1088.3-1088	2.4	
56	Interferon gamma-inducible protein 16 (IFI16) and anti-IFI16 antibodies in primary Sjögren's syndrome: findings in serum and minor salivary glands. <i>Reumatismo</i> , 2015 , 67, 85-90	1.1	5
55	Plant-Derived Chimeric Virus Particles for the Diagnosis of Primary Sjögren Syndrome. <i>Frontiers in Plant Science</i> , 2015 , 6, 1080	6.2	16
54	T Regulatory and T Helper 17 Cells in Primary Sjögren's Syndrome: Facts and Perspectives. <i>Mediators of Inflammation</i> , 2015 , 2015, 243723	4.3	44

53	SAT0377 Interferon Gamma-Inducible Protein 16 (IFI16) in Primary Sjögren's Syndrome: A Novel Player in Disease Pathogenesis?. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 795.4-796	2.4	
52	EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide. <i>RMD Open</i> , 2015 , 1, e000022	5.9	150
51	Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis. <i>Expert Opinion on Biological Therapy</i> , 2015 , 15, 1727-37	5.4	24
50	Cardiovascular disease in systemic sclerosis. <i>Annals of Translational Medicine</i> , 2015 , 3, 8	3.2	26
49	Serum interleukin-17 in primary Sjögren's syndrome: association with disease duration and parotid gland swelling. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 129	2.2	15
48	One year in review 2015: Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 259-71	2.2	27
47	Correlation between clinimetric approach and German US7 score in rheumatoid arthritis patients treated with tocilizumab: a pilot study. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 445	2.2	
46	Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 449-56	2.2	51
45	Myositis in primary Sjögren's syndrome: data from a multicentre cohort. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 457-64	2.2	26
44	Primary Sjögren's syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. <i>Rheumatology</i> , 2014 , 53, 839-44	3.9	129
43	CD4(-)CD8(-) T-cells in primary Sjögren's syndrome: association with the extent of glandular involvement. <i>Journal of Autoimmunity</i> , 2014 , 51, 38-43	15.5	53
42	Diagnosis and classification of autoimmune hypophysitis. <i>Autoimmunity Reviews</i> , 2014 , 13, 412-6	13.6	62
41	Unmasking the pathogenic role of IL-17 axis in primary Sjögren's syndrome: a new era for therapeutic targeting?. <i>Autoimmunity Reviews</i> , 2014 , 13, 1167-73	13.6	29
40	Rituximab in primary Sjögren's syndrome: a ten-year journey. <i>Lupus</i> , 2014 , 23, 1337-49	2.6	19
39	The classification criteria for Sjögren syndrome: issues for their improvement from the study of a large Italian cohort of patients. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, e35	2.4	6
38	The role of T helper 17 cell subsets in Sjögren's syndrome: similarities and differences between mouse model and humans. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, e42	2.4	6
37	Is minor salivary gland biopsy more than a diagnostic tool in primary Sjögren's syndrome? Association between clinical, histopathological, and molecular features: a retrospective study. <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 44, 314-24	5.3	54
36	SAT0030 Circulating Endothelial Microparticles and Endothelial Progenitors Cells in Primary Sjögren's Syndrome: New Markers of Chronic Endothelial Damage?. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 599.3-600	2.4	

35	A3.1 Pathogenic role of IL-17 producing double negative (DN) T cells in primary sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, A42.1-A42	2.4	
34	A3.8 Association between clinical, histopathological and molecular features in primary Sjögren's Syndrome: a retrospective study. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, A45.1-A45	2.4	
33	Expansion of regulatory GITR+CD25 low/-CD4+ T cells in systemic lupus erythematosus patients. <i>Arthritis Research and Therapy</i> , 2014 , 16, 444	5.7	35
32	Drugs in induction and treatment of idiopathic inflammatory myopathies. <i>Autoimmunity Highlights</i> , 2014 , 5, 95-100	3.7	5
31	THU0194 Role of Platelets in the Pathogenesis of Osteoarthritis and Biological Effects of Hyaluronic Acid: in Vivo and in Vitro Study. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 248.3-249	2.4	1
30	Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study. <i>Arthritis Research and Therapy</i> , 2013 , 15, R16	5.7	44
29	Cardiovascular risk in rheumatoid arthritis and systemic autoimmune rheumatic disorders: a suggested model of preventive strategy. <i>Clinical Reviews in Allergy and Immunology</i> , 2013 , 44, 14-22	12.3	17
28	The microbial capsular polysaccharide galactoxylomannan inhibits IL-17A production in circulating T cells from rheumatoid arthritis patients. <i>PLoS ONE</i> , 2013 , 8, e53336	3.7	9
27	SAT0212 Pregnancy and fetal outcome in patients with an established diagnosis of primary sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 543.3-544	2.4	
26	Outcome of pregnancy in Italian patients with primary Sjögren syndrome. <i>Journal of Rheumatology</i> , 2013 , 40, 1143-7	4.1	22
25	Images in clinical medicine: Unusual bursal fluid. <i>New England Journal of Medicine</i> , 2013 , 369, 1945	59.2	1
24	Characterization of a new regulatory CD4+ T cell subset in primary Sjögren's syndrome. <i>Rheumatology</i> , 2013 , 52, 1387-96	3.9	46
23	IL-17-producing CD4-CD8- T cells are expanded in the peripheral blood, infiltrate salivary glands and are resistant to corticosteroids in patients with primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 286-92	2.4	73
22	SAT0398 Diagnostic value of anti mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: A multicentric study by firma group. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 607.1-607	2.4	1
21	AB0037 CD4+CD25-GITR+regulatory T cells are expanded in the blood, display suppressive function and are inversely correlated with disease activity in patients with primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 639.12-639	2.4	
20	FRI0282 Serological biomarkers of b-cell lymphoproliferative disorders in patients with primary sjögren's syndrome: retrospective study in a large italian cohort. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A469.3-A470	2.4	
19	SAT0219 Prevalence and predictive role of traditional cardiovascular risk factors in a cohort of sjögren's syndrome patients. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 546.1-546	2.4	
18	FRI0001 IL-17 producing-DN T cells are expanded in the blood, infiltrate salivary glands and are resistant to corticosteroids in sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 311.1-311	2.4	

17	THU0192 Myositis in primary sjögren's syndrome: Data from a multicenter cohort. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 220.2-220	2.4	
16	THU0129 Selective elimination of pathogenic TH17 cells from peripheral blood of rheumatoid arthritis patients by a purified fungal polysaccharide. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 198.3-198	2.4	
15	AB0952 Intra-articular low molecular weight hyaluronate reduces platelet influx and matrix metalloproteinase-2 levels in synovial fluid of patients with knee osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 693.3-693	2.4	
14	THU0174 Endothelial microparticles and circulating endothelial progenitor cells in primary sjögren's syndrome patients: A potential marker of endothelial damage?. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 214.2-214	2.4	
13	SAT0187 Immunomodulatory effects of human umbilical cord wharton jelly-derived mesenchymal stem cells (HUCMS) on circulating T-cell subsets in patients with sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 534.3-535	2.4	
12	A3.4 CD3+CD4 ⁺ CD8 ⁻ Double Negative Th17 Cells: New Insights in the Pathogenesis of Primary Sjögren's Syndrome. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A14.2-A15	2.4	
11	Ultrasound revealing subclinical enthesopathy at the greater trochanter level in patients with spondyloarthritis. <i>Clinical Rheumatology</i> , 2012 , 31, 463-8	3.9	8
10	Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature. <i>Autoimmunity Reviews</i> , 2012 , 11, 815-20	13.6	41
9	Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new. <i>Clinical and Developmental Immunology</i> , 2012 , 2012, 823085		108
8	Beneficial cardiovascular effects of low-dose glucocorticoid therapy in inflammatory rheumatic diseases. <i>Journal of Rheumatology</i> , 2012 , 39, 1758-60; author reply 1761	4.1	6
7	Aortic stiffness is increased in polymyalgia rheumatica and improves after steroid treatment. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1151-6	2.4	27
6	Increased levels of circulating DNA in patients with systemic autoimmune diseases: A possible marker of disease activity in Sjögren's syndrome. <i>Lupus</i> , 2011 , 20, 928-35	2.6	40
5	Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: two faces of the same coin. <i>Arthritis Care and Research</i> , 2011 , 63, 178-83	4.7	71
4	Atherosclerotic vascular damage and rheumatoid arthritis: a complex but intriguing link. <i>Expert Review of Cardiovascular Therapy</i> , 2010 , 8, 1309-16	2.5	11
3	Role of regulatory T cells in rheumatoid arthritis: facts and hypothesis. <i>Autoimmunity Highlights</i> , 2010 , 1, 45-51	3.7	13
2	How early is the atherosclerotic risk in rheumatoid arthritis?. <i>Autoimmunity Reviews</i> , 2010 , 9, 701-7	13.6	37
1	Cardiac involvement in systemic rheumatic diseases: An update. <i>Autoimmunity Reviews</i> , 2010 , 9, 849-52	13.6	58